FENC Fennec Pharmaceuticals Inc.
NEUTRAL
Impact: 3/10
PRESS-RELEASE
Press release: earnings
Final — all horizons settled through T+60d
FENC ▲ +18.47% at T+60d
NEUTRAL call ✓ call won +18.47% · α vs SPY +6.95% · entry $7.47 → $8.85
Currently $9.00 · +20.48% from $7.47 entry
T+1d
+2.41%
call +2.41% · α +2.68%
$7.65
settled 3mo ago
T+5d
-17.40%
call -17.40% · α -16.69%
$6.17
settled 3mo ago
T+20d
-15.66%
call -15.66% · α -21.71%
$6.30
settled 8w ago
T+60d
+18.47%
call +18.47% · α +6.95%
$8.85
settled 24h ago
Price Chart
Loading chart...
Executive Summary
Fennec Pharmaceuticals announced it will release its full year and fourth quarter 2025 financial results on March 24, 2026, followed by a management conference call. The press release contains no actual financial data, only logistical details for the upcoming earnings announcement.
Actionable Insight
Traders should monitor the March 24 earnings release and call for revenue, EPS, and guidance updates, particularly on PEDMARK/PEDMARQSI sales trends and U.S. commercial execution.
Key Facts
- Fennec Pharmaceuticals will release full year and Q4 2025 financial results on March 24, 2026, before market open.
- Management will host a conference call and webcast on March 24, 2026, at 8:30 a.m. ET to discuss results.
- No financial figures (revenue, EPS, etc.) were disclosed in this announcement.
- PEDMARK is approved in the U.S. and PEDMARQSI in Europe, U.K., with commercial availability in U.K. and Germany.
- Norgine Pharmaceuticals holds exclusive rights to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.
Financial Impact
None disclosed — actual financial results not included in this release
Risk Factors
- Lack of disclosed financials limits near-term trading catalysts ahead of the March 24 release.
- Revenue concentration in a single product (PEDMARK) creates execution and adoption risk.
Market Snapshot
Exchange
Nasdaq
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258049 |
13 reports for FENC
100%
Hit rate
best @ T+60▲ +20.32%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
21d ago
|
8-K
| $9.89 $9.88 | ▼ −0.10% | ▼ −1.18% | $9.00 (−9.00%) |
|
May 18, 2026
25d ago
|
8-K
| $9.76 $9.97 | ▲ +2.15% | ▼ −0.15% | $9.00 (−7.79%) |
|
May 14, 2026
4w ago
|
Press Release
| $9.24 $9.97 | ▲ +7.90% | ▲ +8.62% | $9.00 (−2.60%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.90 $6.77 | ▼ −1.88% | ▼ −3.39% | $9.00 (+30.43%) |
|
Apr 28, 2026
6w ago
|
8-K
| $6.26 $7.18 | ▲ +14.70% | ▲ +11.59% | $9.00 (+43.77%) |
|
Apr 22, 2026
7w ago
|
8-K
| $6.66 $6.26 | ▼ −6.01% | ▼ −7.48% | $9.00 (+35.14%) |
|
Apr 7, 2026
9w ago
|
8-K
| $6.49 $6.50 | ▲ +0.15% | ▼ −3.36% | $9.00 (+38.67%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $6.32 $6.25 | ▼ −1.11% | ▼ −6.44% | $9.00 (+42.41%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $6.02 $6.15 | ▲ +2.16% | ▲ +2.58% | $9.00 (+49.50%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $7.47 $6.17 | ▼ −17.40% | ▼ −16.69% | $9.00 (+20.48%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Mon (49h 36m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access